Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline
KYOTO, Japan , July 21, 2026 /PRNewswire/ -- Rege Nephro Co., Ltd. ("Rege Nephro"), a clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicine and drug discovery, today announced the closing of a financing round totaling approximately US$10.6 million through the issuance of J-KISS (Japan-Keep It Simple Security) share acquisition rights. The proceeds are expected to support commercialization activities for RN-014, the company's lead candidate for autosomal dominant polycystic kidney disease (ADPKD), advance its iPS cell-derived regenerative medicine program RN-032, and fund continued research and development activities. The financing is intended to support the company's growth through its anticipated Series C financing and beyond.
×
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
kF= EJA6lQ5:D4Qmk=:mkDEC@?8mq24<8C@F?5 @7 E96 uF?5:?8k^DEC@?8mk^=:mk^F=m
kAm#686 }6A9C@ :D 565:42E65 E@ 56G6=@A:?8 :??@G2E:G6 E96C2A:6D 2?5 >65:42= E649?@=@8:6D 7@C A2E:6?ED H:E9 <:5?6J 5:D62D6D H9@ 4FCC6?E=J 92G6 =:>:E65 EC62E>6?E @AE:@?D]k^Am
kAm%96 4@>A2?JVD =625 AC@8C2>[ #}\_`c[ C646?E=J C624965 {!{' W{2DE !2E:6?E {2DE ':D:EX :? :ED !92D6 a2 4=:?:42= EC:2=[ >2C<:?8 2? :>A@CE2?E >:=6DE@?6] #}\_`c :D 2 D>2==\>@=64F=6 E96C2A6FE:4 42?5:52E6 :56?E:7:65 E9C@F89 D4C66?:?8 FD:?8 2? :!$ 46==\56C:G65 ps!zs 5:D62D6 >@56=[ 2?5 2?2=JD:D @7 !92D6 a2 4=:?:42= EC:2= 52E2 :D 4FCC6?E=J F?56CH2J]k^Am
kAmx? 255:E:@?[ #}\_ba[ 2? :!$ 46==\56C:G65 C686?6C2E:G6 >65:4:?6 AC@8C2> 32D65 @? C6?2= ?6A9C@? AC@86?:E@C 46==D[ 92D 4@>A=6E65 AC@46DD 56G6=@A>6?E :? AC6A2C2E:@? 7@C ?@?4=:?:42= DEF5:6D 2?5 :D AC@8C6DD:?8 E@ E96 ?6IE DE286]k^Am
kAm%96 7:?2?4:?8 H:== DFAA@CE 4@?E:?F65 25G2?46>6?E @7 E96D6 4@C6 AC@8C2>D H9:=6 DEC6?8E96?:?8 E96 4@>A2?JVD =@?8\E6C> 8C@HE9 DEC2E68J]k^Am
kF= EJA6lQ5:D4Qmk=:mkDEC@?8muFEFC6 $EC2E68J 2?5 &D6 @7 !C@4665Dk^DEC@?8mk^=:mk^F=m
kAm%96 42A:E2= C2:D65 H:== 36 2==@42E65 24C@DD 7@FC <6J AC:@C:E:6Dik^Am
kAm`] #}\_`c r@>>6C4:2=:K2E:@? 2?5 v=@32= {:46?D:?8 p4E:G:E:6Dk^Am
kAmqF:=5:?8 @? :?D:89ED 86?6C2E65 7C@> E96 !92D6 a2 4=:?:42= EC:2=[ #686 }6A9C@ A=2?D E@ AFCDF6 8=@32= =:46?D:?8 2?5 A2CE?6C:?8 @AA@CEF?:E:6D 7@C #}\_`c H9:=6 4@?E:?F:?8 56G6=@A>6?E 24E:G:E:6D 2:>65 2E 7FCE96C 6G2=F2E:?8 E96 AC@8C2>VD E96C2A6FE:4 A@E6?E:2=]k^Am
kAma] $FAA@CE:?8 }@?4=:?:42= s6G6=@A>6?E @7 #}\_bak^Am
kAmu@==@H:?8 E96 4@>A=6E:@? @7 AC@46DD 56G6=@A>6?E 7@C #}\_ba[ E96 4@>A2?J H:== 25G2?46 #}\_ba :?E@ ?@?4=:?:42= DEF5:6D E@ 6DE23=:D9 E96 7@F?52E:@? 7@C 7FEFC6 4=:?:42= EC:2=D]k^Am
kAmb] tIA2?5:?8 s:D4@G6CJ #6D62C49 2?5 z:5?6J #686?6C2E:@? !C@8C2>Dk^Am
kAm%96 4@>A2?J H:== 4@?E:?F6 E@ :?G6DE :? 5:D4@G6CJ 2?5 EC2?D=2E:@?2= C6D62C49[ :?4=F5:?8 ?6IE\86?6C2E:@? <:5?6J C686?6C2E:@? E649?@=@8:6D 2?5 7FEFC6 A:A6=:?6 42?5:52E6D] #686 }6A9C@ F=E:>2E6=J 2:>D E@ 56G6=@A E96C2A:6D E92E :>AC@G6 @FE4@>6D 2?5 BF2=:EJ @7 =:76 7@C A2E:6?ED H:E9 <:5?6J 5:D62D6 H9:=6 C65F4:?8 AC@8C6DD:@? E@ <:5?6J 72:=FC6]k^Am
kAmc] $EC6?8E96?:?8 ~C82?:K2E:@?2= r2A23:=:E:6Dk^Am
kAm%@ DFAA@CE 4@?E:?F65 8C@HE9[ #686 }6A9C@ A=2?D E@ 6IA2?5 :ED E62> 3J C64CF:E:?8 D4:6?E:7:4[ 4=:?:42= 56G6=@A>6?E[ 2?5 3FD:?6DD 56G6=@A>6?E AC@76DD:@?2=D H:E9 DA64:2=:K65 6IA6CE:D6]k^Am
kAm%9C@F89 E9:D 7:?2?4:?8[ #686 }6A9C@ D66<D E@ 25G2?46 :ED A:A6=:?6 H9:=6 DEC6?8E96?:?8 E96 @A6C2E:@?2= 7@F?52E:@? C6BF:C65 E@ DFAA@CE 7FEFC6 8C@HE9 2?5 =@?8\E6C> G2=F6 4C62E:@?]k^Am
kF= EJA6lQ5:D4Qmk=:mkDEC@?8m{:DE @7 E96 :?G6DE@CDk^DEC@?8m Wx? 2=A9236E:42= @C56CXk^=:mk^F=m
kAmpC4FD $@FE9 t2DE pD:2k^Am
kAmqpf '6?EFC6 r2A:E2= r~#!k^Am
kAmr9FD9:? '6?EFC6 r2A:E2= r@][ {E5]k^Am
kAmsrx !2CE?6CD r@][ {E5]k^Am
kAmypur~ vC@FA r@][ {E5]k^Am
kAmyxr '6?EFC6 vC@HE9 x?G6DE>6?ED r@][ {E5]k^Am
kAmzJ@D9:? $@4:2= r2A:E2= r@][ {E5]k^Am
kAmzJ@E@ &?:G6CD:EJ x??@G2E:@? r2A:E2= r@][ {E5]k^Am
kAm|:EDF3:D9: &uy r2A:E2= r@][ {E5]k^Am
kAm#p!\wx r@][ {E5]k^Am
kAm$!p#) pDD6E |2?286>6?E r@][ {E5]k^Am
kAm%2:p? %649?@=@8:6D r@CA]k^Am
kAm%~w~ w~{sx}v$ r~][ {%s]k^Am
k5:G 4=2DDlQ!#}0x>365565pDD6E#676C6?46Q :5lQs:GpDD6E!=246w@=56CdchhQmkAmk:>8 DC4lQ9EEADi^^>>I]AC?6HDH:C6]4@>^>65:2^|$`ggcega^a_ae_f`f_b`edfts%0:>2860`];A8n:5l~pafegdecQ E:E=6lQQ 2=ElQQ ^mk^Amk^5:Gm
kF= EJA6lQ5:D4Qmk=:mkDEC@?8mr@>>6?E 7C@> p<:7F>: |@C:?2<2[ #6AC6D6?E2E:G6 s:C64E@C 2?5 rt~ @7 #686 }6A9C@ik^DEC@?8mk^=:mk^F=m
kAmQ%9:D 7F?5:?8 C@F?5 >2C<D 2? :>A@CE2?E >:=6DE@?6 2D H6 25G2?46 #}\_`c E@H2C5 4@>>6C4:2=:K2E:@? 2?5 2446=6C2E6 56G6=@A>6?E @7 #}\_ba[Q D2:5 p<:7F>: |@C:?2<2[ #6AC6D6?E2E:G6 s:C64E@C 2?5 rt~ @7 #686 }6A9C@] Qx H@F=5 =:<6 E@ 6IAC6DD >J D:?46C6 8C2E:EF56 E@ @FC :?G6DE@CD 7@C E96:C DFAA@CE 2?5 4@?7:56?46 :? @FC G:D:@? 2?5 AC@8C6DD] (:E9 #}\_`c 92G:?8 4@>A=6E65 :ED !92D6 a2 4=:?:42= EC:2= 2?5 #}\_ba 25G2?4:?8 E@H2C5 :ED ?6IE DE286 @7 56G6=@A>6?E[ H6 36=:6G6 E96 4@>A2?J :D H6== A@D:E:@?65 7@C 4@?E:?F65 8C@HE9] (6 C6>2:? 4@>>:EE65 E@ 255C6DD:?8 F?>6E >65:42= ?665D :? <:5?6J 5:D62D6 E9C@F89 :??@G2E:G6 >65:4:?6D 2?5 C686?6C2E:G6 E96C2A:6D 32D65 @? :!$ 46== E649?@=@8J]Qk^Am
kF= EJA6lQ5:D4Qmk=:mkDEC@?8mp3@FEÂ #686 }6A9C@ r@][ {E5]k^DEC@?8mk^=:mk^F=m
kAm#686 }6A9C@ r@][ {E5] :D 2 4=:?:42=\DE286 3:@E649?@=@8J 4@>A2?J E92E =6G6C286D D4:6?E:7:4 5:D4@G6C:6D @C:8:?2E:?8 7C@> E96 C6D62C49 @7 !C@76DD@C z6?;: ~D27F?6 2E zJ@E@ &?:G6CD:EJVD r6?E6C 7@C :!$ r6== #6D62C49 2?5 pAA=:42E:@? Wr:#pX]k^Am
kAm%96 4@>A2?J :D 56G6=@A:?8 :??@G2E:G6 E96C2A:6D 7@C <:5?6J 5:D62D6D 32D65 @? :!$ 46== E649?@=@8J[ H:E9 E96 8@2= @7 6IA2?5:?8 EC62E>6?E @AE:@?D 7@C A2E:6?ED H:E9 D6C:@FD 2?5 5:77:4F=E\E@\EC62E 4@?5:E:@?D]k^Am
kAm&#{i k2 9C67lQ9EEADi^^HHH]C686?6A9C@]4@];A^6?Q E2C86ElQ03=2?<Q C6=lQ?@7@==@HQm9EEADi^^HHH]C686?6A9C@]4@];A^6?k^2mk^Am
k5:G 4=2DDlQ!#}0x>365565pDD6E#676C6?46Q :5lQs:GpDD6E!=246w@=56C_QmkAmk:>8 DC4lQ9EEADi^^>>I]AC?6HDH:C6]4@>^>65:2^|$`ggcf`b^C686?6A9C@\=@8@\J@<@\{@8@];A8n:5l~pafegedfQ E:E=6lQQ 2=ElQQ ^mk^Amk^5:Gm
kA :5lQ!&#{Qmk:>8 E:E=6lQr:D:@?Q H:5E9lQ`aQ 96:89ElQ`aQ 2=ElQr:D:@?Q DC4lQ9EEADi^^6586]AC?6HDH:C6]4@>^4^:>8^72G:4@?]A?8nD?lr}_eghbU2>AjD5la_ae\_f\a`Q ^m ':6H @C:8:?2= 4@?E6?E E@ 5@H?=@25 >F=E:>65:2ik2 :5lQ!#}&#{Q C6=lQ?@7@==@HQ 9C67lQ9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^C686\?6A9C@\D64FC6D\2AAC@I:>2E6=J\FD`_\e\>:==:@?\E@\25G2?46\C?\_`c\E@H2C5\4@>>6C4:2=:K2E:@?\b_agagcec]9E>=Q E2C86ElQ03=2?<Qm9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^C686\?6A9C@\D64FC6D\2AAC@I:>2E6=J\FD`_\e\>:==:@?\E@\25G2?46\C?\_`c\E@H2C5\4@>>6C4:2=:K2E:@?\b_agagcec]9E>=k^2mk^Am
kAm$~&#rt #686 }6A9C@ r@][ {E5]k^Am
kAmk:>8 2=ElQQ DC4lQ9EEADi^^CE]AC?6HDH:C6]4@>^CE]8:7n}6HDxE6>x5lr}_eghbU2>Aj%C2?D>:DD:@?0x5la_ae_fa`____!#0}t($0&$!#00000r}_eghbU2>Ajs2E6x5la_ae_fa`Q DEJ=6lQ3@C56Ci_AIj H:5E9i`AIj 96:89Ei`AIjQ ^mk^Am
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.